Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

Sanjiv S. Agarwala, MD
Published: Friday, Jul 20, 2018



Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

In a phase Ib/II study, the small molecular inhibitor entinostat was paired with the PD-1 inhibitor pembrolizumab for the treatment of patients with non–small cell lung cancer, melanoma, and mismatch-repair proficient colorectal cancer. In all cases, these patients were refractory to pembrolizumab alone.

Data from the study, which were presented at the 2018 ASCO Annual Meeting, show that the addition of entinostat resulted in an 18% confirmed overall response rate. Agarwala adds that 29% of patients who had disease progression became stable under the combination. Primary endpoints of the study were safety and efficacy.


Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

In a phase Ib/II study, the small molecular inhibitor entinostat was paired with the PD-1 inhibitor pembrolizumab for the treatment of patients with non–small cell lung cancer, melanoma, and mismatch-repair proficient colorectal cancer. In all cases, these patients were refractory to pembrolizumab alone.

Data from the study, which were presented at the 2018 ASCO Annual Meeting, show that the addition of entinostat resulted in an 18% confirmed overall response rate. Agarwala adds that 29% of patients who had disease progression became stable under the combination. Primary endpoints of the study were safety and efficacy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x